<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549263</url>
  </required_header>
  <id_info>
    <org_study_id>AVR110549</org_study_id>
    <nct_id>NCT00549263</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of SB797620 in Healthy Japanese Volunteers</brief_title>
  <official_title>A Bioequivalence Study With a Combination Tablet Formulation of Rosiglitazone (RSG) and Glimepiride (GLIM)(4mg/2mg) Compared to Concomitant Dosing of RSG 4mg Tablet and GLIM 1mg Commercial Tablet x 2 (4mg+2mg) in Japanese Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether the Drug levels in plasma after combination formulation tablet
      dosing (SB797620) and separate formulation tablets dosing (rosiglitazone and glimepiride) to
      Japanese Healthy volunteer would be the same or not.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No subjects enrolled, bio equivalence study, canceled before active.
  </why_stopped>
  <start_date>February 2008</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug levels on Day 1</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events on Day 1</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory test on Day 1</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs and 12-lead ECG on Day 1</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB797620</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

          -  They are Japanese males.

          -  Aged 20 to 55 years, inclusive.

          -  They have body mass index at screening within 18.5-25.0. Body weight 50-80kg.

          -  AST(GOT), ALT(GPT), gumma-GPT and ALP: below the upper normal range

          -  They are capable of giving written informed consent, which includes compliance with
             the requirements and restrictions listed in the consent form.

          -  They could refrain from smoking during hospitalization.

          -  They are able to attend all visits and complete the study.

        Exclusion Criteria:

          -  The subject has any clinically relevant abnormality on medical examination, vital
             sign, clinical laboratory test or medical history at screening in the medical opinion
             of the investigator or the subject has a medical history that is not considered as
             eligible for inclusion in this study by the investigator.

          -  Known hepatic or biliary abnormalities such as Gilbert's syndrome.

          -  Use of insulin or oral anti-hyperglycemic agents within the past 3 months prior to
             screening.

          -  Subjects who have a history of lactose intolerance.

          -  The subject has an allergy for any drug or idiosyncrasy. This excludes a pollen
             allergy without current symptoms.

          -  The subject is currently participating in another clinical study or post-marketing
             study in which the subject is or will be exposed to an investigational or a
             non-investigational drug or device.

          -  The subject has participated in a clinical study with an investigational or a
             non-investigational drug or device during the previous 4 months.

          -  The subject has a screening ECG with a QTc value outside the range 320 to 450msec, a
             PR interval of &gt;230msec and/or a QRS interval of &gt;120msec.

          -  The subject has a heart rate outside the range 40 to 110 bpm at screening.

          -  The subject has donated a unit of blood &quot;&gt;400mL&quot; within the previous 4 months or
             &quot;&gt;200mL&quot; within the previous 1 month.

          -  The subject is currently taking regular (or a course of) medication (including
             prescribed drug, over-the-counter medication and herbal remedies), and can not cease
             them 30 days prior to th first study drug dosing.

          -  The subject has a history or current conditions of drug abuse or alcoholism.

          -  History of alcohol consumption in the past six months exceeding 7 drinks per week
             (where 1 drink is 350mL in terms of beer)

          -  The subject is positive for syphilis, HBs antigen, HCV antibody, HIV antigen/antibody,
             HTLV-1 antibody.

          -  The subject is positive for urine drug screening.

          -  Current history of hypo- or hyperglycemia as indicated by serum glucose values below
             the laboratory-specified reference range or =110 mg/dL, at screening, or as reported
             by the subject.

          -  History of surgical procedures that might affect the absorption of RSG or GLIM (e.g.,
             partial/total gastrectomy, cholecystectomy).

          -  History of hypersensitivity to thiazolidinediones, sulfonylureas or compounds with
             similar chemical structures.

          -  History of sensitivity to heparin, heparin-induced thrombocytopenia or sensitivity to
             any of the study medications or components thereof.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2007</study_first_submitted>
  <study_first_submitted_qc>October 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2007</study_first_posted>
  <last_update_submitted>February 19, 2015</last_update_submitted>
  <last_update_submitted_qc>February 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Bioequivalence</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

